Binding characteristics of remoxipride and its metabolites to dopamine D2 and D3 receptors.

@article{Mohell1993BindingCO,
  title={Binding characteristics of remoxipride and its metabolites to dopamine D2 and D3 receptors.},
  author={Nina Mohell and Maria S{\"a}llemark and Susanne Rosqvist and Aa. Malmberg and Thomas H{\"o}gberg and David M. Jackson},
  journal={European journal of pharmacology},
  year={1993},
  volume={238 1},
  pages={
          121-5
        }
}
The substituted benzamide, remoxipride, is a new atypical antipsychotic agent with good clinical efficacy and low extrapyramidal side-effect potential. In the present study, the in vitro receptor binding properties of remoxipride and several of its metabolites to rat striatal dopamine D2 and cloned human dopamine D2A and D3 receptors were investigated. Remoxipride bound to [3H]raclopride-labelled dopamine D2 receptors in rat striatum with an affinity (Ki) of 113 nM. The significantly lower… Expand
Effects of remoxipride's metabolites on dopamine D2 receptors and receptor functions in the rat.
TLDR
Analysis of the effectiveness of the DA receptor blockade after intraperitoneal or subcutaneous administration suggested that FLA 797 (-)/FLA 908 (-) may only contribute marginally to the D2 receptor-blocking activity of remoxipride in the rat, and the weak DA D2 blocking effect of the pyrrolidone metabolites indicated that remxipride is responsible for the clinical action. Expand
Pharmacology of the atypical antipsychotic remoxipride, a dopamine D2 receptor antagonist.
TLDR
In animals, remoxipride has minimal cataleptic effects at doses that block dopamine agonist-induced hyperactivity and these findings are predictive of antipsychotic activity with a low likelihood of extrapyramidal symptoms. Expand
Dopamine D2 blocking activity and plasma concentrations of remoxipride and its main metabolites in the rat
TLDR
It was concluded that the metabolites FLA 797 (−), FLA 908(−), and NCQ 436(−) do not appear to contribute to the antagonism of DA D2 mediated neurotransmission following a low remoxipride dose. Expand
Chapter 5. Recent Advances in Dopamine D3 and D4 Receptor Ligands and Pharmacology
TLDR
Dopamine agonists, such as pergolide and quinpirole, are used in the treatment of Parkinson's disease and are reported to have a higher affinity for the D 3 receptor as compared to the D 2 receptor. Expand
Does the dopamine receptor subtype selectivity of antipsychotic agents provide useful leads for the development of novel therapeutic agents?
TLDR
The receptor-binding profiles of a series of antipsychotic agents are studied and some of the compounds in behavioural assays in the rat are evaluated and speculations on the key-target of clinically interesting antipsychotics (including clozapine) may be of little practical value. Expand
A Review of the Discovery, Pharmacological Characterization, and Behavioral Effects of the Dopamine D2‐Like Receptor Antagonist Eticlopride
TLDR
This review highlights research utilizing this drug and compares it to typical and atypical antipsychotics used clinically and discusses the use of eticlopride in several behavioral models predictive of antipsychotic activity, extrapyramidal side effects (EPS), and learning and memory. Expand
Critical reevaluation of spiperone and benzamide binding to dopamine D2 receptors: evidence for identical binding sites.
TLDR
The results clearly demonstrate that when studied under correct experimental conditions, all four radioligands label an identical receptor population. Expand
Dopamine D2 receptor blockade in vivo with the novel antipsychotics risperidone and remoxipride — an123I-IBZM single photon emission tomography (SPET) study
TLDR
High levels of striatal D2 receptor occupancy in association with remoxipride and risperidone treatment are suggested and argue against modest D2 antagonism as the explanation for the low incidence of EPS associated with these drugs. Expand
Pharmacological Comparison of Antipsychotic Drugs and σ-Antagonists in Rodents
TLDR
Only weak activity of sigma antagonists in the behavioural models widely used to study the antipsychotic drugs is revealed. Expand
Remoxipride shows low propensity to block functional striatal dopamine D2 receptors in vitro.
TLDR
The results demonstrate that remoxipride is significantly weaker in blocking functional striatal dopamine D2 receptors than either of the reference compounds studied and three of the four metabolites. Expand
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 15 REFERENCES
Biochemical pharmacology of the atypical neuroleptic remoxipride
Abstract In vitro receptor ligand binding studies in the rat showed that remoxipride displaced different radioligands at the dopamine D2, but not the D1 receptor. Remoxipride did not blockExpand
Unique binding characteristics of antipsychotic agents interacting with human dopamine D2A, D2B, and D3 receptors.
TLDR
Compared the pharmacological properties of human dopamine (DA) D2A, D2B, and D3 receptors expressed in mammalian cell lines, using [3H]raclopride as a radioligand, clozapine and substituted benzamides and remoxipride, a new antipsychotic agent with low potential to produce extrapyramidal side effects displayed 2-3-fold higher affinity for the D 2B receptor than for theD2A receptor. Expand
Remoxipride, a new potential antipsychotic compound with selective antidopaminergic actions in the rat brain.
TLDR
Results indicate that remoxipride is a potent, selective D2 receptor blocking agent with a preferential action in mesolimbic and extrastriatal dopamine-containing neurons. Expand
Neuropharmacological and behavioural properties of remoxipride in the rat
TLDR
The results suggest that remoxipride, unlike haloperidol, can discriminate between different types of dopamine mediated functions probably by having a preferential action on subpopulations of functionally coupled dopamine D2 receptors. Expand
Effects of remoxipride and some related new substituted salicylamides on rat brain receptors.
A number of potential neuroleptic drugs of the substituted benzamide type have been compared with some reference neuroleptic drugs regarding their affinities for rat brain receptors using in vitroExpand
Cloning of the gene for a human dopamine D4 receptor with high affinity for the antipsychotic clozapine
TLDR
The cloning of a gene that encodes a dopamine receptor gene that has high homology to the human dopamine D2 and D3 receptor genes is reported, which suggests the existence of other types of dopamine receptors which are more sensitive to clozapine. Expand
Comparison of neuroleptic binding characteristics in rat striatum and renal cortex.
TLDR
The binding characteristics of the dopaminergic ligand and the pharmacological properties of the peripheral 3H-spiperone binding site are also different from the DA-1 receptor but seem to resemble those previously reported for dopamine receptors in sympathetic ganglia and adrenal medulla. Expand
Disposition of remoxipride in different species. Species differences in metabolism.
TLDR
The pharmacokinetics and metabolism of the new antipsychotic agent remoxipride was studied in rodents, dogs and human subjects using the unlabelled or the labelled (3H or 14C) drug. Expand
Comparison of the In Vitro Receptor Binding Properties of N‐[3H]Methylspiperone and [3H]Raclopride to Rat and Human Brain Membranes
TLDR
In vitro binding techniques suggest that part of the binding site is exclusively used by NMSP and can only be allosterically interfered with by raclop Ride, and it is proposed that [3H]NMSP binds to an additional set of accessory binding sites, presumably located more distantly from the agonist binding active site than the sites to which [3 H]raclopride binds. Expand
Pharmacology of human dopamine D3 receptor expressed in a mammalian cell line: comparison with D2 receptor.
TLDR
Several agonists and antagonists, previously regarded as autoreceptor-selective, displayed higher affinities at D3 than at D2 receptors, suggesting that they realize differential dopamine receptor subtype occupancy during treatments and that this might be reflected in their clinical profile. Expand
...
1
2
...